Swedish Orphan Biovitrum AB (publ) (SWOBY)
OTCMKTS
· Delayed Price · Currency is USD
15.25
-0.45 (-2.87%)
At close: May 9, 2025
SWOBY Revenue
Swedish Orphan Biovitrum AB had revenue of 6.47B SEK in the quarter ending March 31, 2025, with 3.34% growth. This brings the company's revenue in the last twelve months to 26.24B, up 13.38% year-over-year. In the year 2024, Swedish Orphan Biovitrum AB had annual revenue of 26.03B with 17.65% growth.
Revenue (ttm)
26.24B SEK
Revenue Growth
+13.38%
P/S Ratio
4.22
Revenue / Employee
14.53M SEK
Employees
1,806
Market Cap
11.03B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
Dec 31, 2020 | 15.26B | 1.01B | 7.11% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |